Publications

1. Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)

   Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...

   Report | 08-05-2019

2. Lumacaftor/ivacaftor (Orkambi®) for the treatment of cystic fibrosis

   The National Health Care Institute carried out a marginal assessment in relation to extending the specific conditions for the ...

   Report | 30-04-2019

3. Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis

   The National Health Care Institute carried out an assessment in relation to extending the specific conditions for the medicinal ...

   Report | 24-04-2019

4. Assessment of 'established medical science and medical practice’ - a technical modification

   This report is a supplement to the existing Dutch assessment framework dating form 2015. It can be used to investigate whether an ...

   Report | 23-04-2019

5. Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults

   The National Health Care Institute carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted ...

   Report | 16-04-2019

6. Pitolisant (Wakix®) for the treatment of narcolepsy in adults

   The National Health Care Institute  carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug ...

   Report | 15-04-2019

7. Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea

   The National Health Care Institute carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is ...

   Report | 09-04-2019

8. Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions

   The National Health Care Institute carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be ...

   Report | 02-04-2019

9. Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

   The National Health Care Institute has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of ...

   Report | 01-04-2019

10. Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)

    Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal  product ...

    Report | 25-03-2019